slotsdreamer US approves first-ever obstructive sleep apnea drug

pulse slots

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep apnea medication. 

Zepbound or Tirzepatide is an injectable drug that the company designed as an obesity treatment. 

READ: Scientists may have found the purpose of sleep

Article continues after this advertisement

The Food and Drug Administration, however, approved it for this health condition due to the results of the SURMOUNT-OSA phase 3 clinical trials. 

FEATURED STORIES TECHNOLOGY ChatGPT can now talk with the voice of Santa Claus TECHNOLOGY US developing topical vaccine that you rub on the skin TECHNOLOGY AI agents will become brand ambassadors in 'Agentic Era' – study How does this sleep apnea treatment work?

Learn more about a new treatment option for moderate-to-severe obstructive sleep apnea and obesity: https://t.co/1nzR5AwyFH pic.twitter.com/gdv4en883F

— Eli Lilly and Company (@EliLillyandCo) December 20, 2024

The FDA explains that Tirzepatide works by activating receptors of hormones from the intestine. 

Robert Velghe, a Dutch executive at OmegaPro, was arrested Tuesday, the reports said, after Andreas Szakacs, a Swede who was among the firm’s founders, was arrested in July.

Consequently, the drug reduces body weight, which improves obstructive sleep apnea (OSA).

Article continues after this advertisement

The clinical trials show that Zepbound reduced breathing disruptions by 25 to 29 per hour instead of five to six with a placebo.

Article continues after this advertisement

It mitigated symptoms for 50% of participants who undergo PAP or Positive Airway Pressure) and for 42% of non-PAP patients.

Article continues after this advertisement

Moreover, those who took Zepbound lost 18% to 20% or 45 lbs to 50 lbs in body weight. 

Dan Skovronsky, Eli Lilly’s chief scientific officer, lauded the results in a TIME report:

Article continues after this advertisement

“This is the first pharmacologic therapy that can treat obstructive sleep apnea in this way,” Skovronsky said. 

“Obstructive sleep apnea is still poorly diagnosed. But this is a disease that itself carries cardiovascular risk, as does obesity, so it’s great to treat both.”

“We… have proven that when you treat with Tirzepatide, you remove some fat and the airway can stay open,” he added. 

Cleveland Clinic explains obstructive sleep apnea blocks a person’s airway and restricts oxygen flow.

In response, the person’s survival reflex wakes them to resume breathing. 

“Too often, obstructive sleep apnea is brushed off as ‘just snoring’ – but it’s far more than that,” Project Sleep CEO Julie Flygare told Reuters.

Aside from loud sleep, it could cause fatigue, mood changes, insomnia, headaches, and other health complications. 

Your subscription could not be saved. Please try again. Your subscription has been successful.

Subscribe to our daily newsletter

SIGN ME UP

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TIME says this sleep apnea and obesity treatment showed the potential to mitigate heart failure and kidney disease in Lilly’s other studies.slotsdreamer

TOPICS: drug, technology READ NEXT US approves first-ever obstructive sleep apnea drug Learn the top skills for career growth in 2025 EDITORS' PICK EDITORIAL: Overcoming adversity in 2025 LeBron turns 40, says he could play ‘another 5 or 7 years’ in NBA Timely DOH reminder: Keep lungs, heart healthy Wet, cloudy New Year's Eve in many parts of PH BFP to public: Observe New Year's Eve fire prevention measures Legarda’s New Year’s message: ‘New opportunities to dream bigger’ MOST READ Palace still studying postponement of BARMM elections Honeymoons, birthdays, first foreign trips end in tragic plane crash BIZ BUZZ: Finally, Four Seasons coming to PH Budget critics: Veto still left ‘pork’ intact Follow @FMangosingINQ on Twitter --> View comments